Disruption of Twist-BRD4 interaction by BET-specific inhibitors in vitro and in vivo have been shown to reduce WNT5A expression and inhibit tumorigenicity and invasion of basal-like breast cancer [62]. The gene discussed is TWIST1; the disease is breast cancer.